We are live on ! Find out more
FHTX icon

Foghorn Therapeutics

79 hedge funds and large institutions have $372M invested in Foghorn Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more call options, than puts

Call options by funds: $92K | Put options by funds: $22K

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

64% more capital invested

Capital invested by funds: $227M → $372M (+$146M)

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

10% more funds holding

Funds holding: 7279 (+7)

1% more ownership

Funds ownership: 71.29%72.29% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
79
Holders Change
+7
Holders Change %
+9.72%
% of All Funds
1.13%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
29
Reduced
19
Closed
6
Calls
$92K
Puts
$22K
Net Calls
+$70K
Net Calls Change
+$46K

FHTX Hedge Fund Activity: Q3 2024 in Review

79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2024, worth a combined $372M — up 64% from $227M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new FHTX positions and 6 closed out — a net gain of 7 holders — while 29 added to existing stakes and 19 trimmed.

The largest buyer was Vanguard Group, adding an estimated $4.87M. The largest seller was Artal Group, exiting entirely with an estimated $4.14M sold.

  • 79 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2024, up from 72 in Q2 2024.
  • Funds reported $372M of Foghorn Therapeutics stock for Q3 2024, up 64% quarter-over-quarter.
  • 13 funds opened new Foghorn Therapeutics positions in Q3 2024 and 6 closed out, a net change of +7 holders.
  • The largest Foghorn Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $4.87M added.
  • The largest Foghorn Therapeutics seller in Q3 2024 was Artal Group, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2024.